Skip to main content
. 2023 Jun 18;11(3):343–360. doi: 10.1007/s40487-023-00234-7
Why carry out this study?
The use of biomarker tests to guide treatment in patients with early-stage non-small cell lung cancer (eNSCLC) is not well understood in the real-world setting.
This study fills a gap in knowledge by examining the real-world biomarker test utilization and subsequent treatment over 11 years in a national sample of adult patients with eNSCLC.
What was learned from the study?
This study suggests a high biomarker testing rate, with various biomarker testing rates increasing over the last decade in patients with eNSCLC in the US.
In patients who received the five most commonly used biomarker tests, almost all received a test before the initiation of a systemic treatment.
With the rapidly evolving treatment landscape and testing recommendations for eNSCLC, future research is needed to understand whether biomarker testing has improved optimal treatment decision making and long-term survival outcomes for patients with eNSCLC.